Pfeiffer, Sebastian

[["dc.bibliographiccitation.firstpage","900"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.lastpage","906"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Götze, Katharina S."],["dc.contributor.author","Müller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Brümmendorf, Tim H."],["dc.contributor.author","Bug, Gesine"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Stadler, Michael"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Blau, Igor W."],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Metz, Michael"],["dc.contributor.author","Detken, Sven"],["dc.contributor.author","Seraphin, Jörg"],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Böhme, Angelika"],["dc.contributor.author","Schmidt, Burkhard C."],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:22:10Z"],["dc.date.available","2018-11-07T09:22:10Z"],["dc.date.issued","2013"],["dc.description.abstract","The gold standard of cytogenetic analysis in myelodysplastic syndromes (MDS) is conventional chromosome banding (CCB) analysis of bone marrow (BM) metaphases. Most aberrations can also be detected by fluorescence-in situ-hybridization (FISH). For this prospective multicenter German diagnostic study (www.clinicaltrials.gov: #NCT01355913) 360 patients, as yet, were followed up to 3 years by sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood (PB) cells using comprehensive FISH probe panels, resulting in a total number of 19,516 FISH analyses. We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB. (C) 2013 Elsevier Ltd. All rights reserved."],["dc.description.sponsorship","Celgene(R) Germany"],["dc.identifier.doi","10.1016/j.leukres.2013.03.019"],["dc.identifier.isi","000321111900012"],["dc.identifier.pmid","23623559"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29278"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0145-2126"],["dc.title","Molecular cytogenetic monitoring from CD34+peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","JDDG Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Brehmer, Franziska"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.contributor.author","Daeschlein, G."],["dc.contributor.author","Ahmed, R."],["dc.contributor.author","Pfeiffer, S."],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Simon, D."],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Wandke, Dirk"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T09:19:10Z"],["dc.date.available","2018-11-07T09:19:10Z"],["dc.date.issued","2013"],["dc.format.extent","10"],["dc.identifier.isi","000324332500029"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28574"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.issn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.title","The Treatment of chronic venous Leg Ulcers with direct Plasma (PlasmaDerm (R) VU 2010): Results of a single center, two-arm, open-label, randomized, controlled Trial"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","589"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","600"],["dc.bibliographiccitation.volume","265"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Wolff-Menzler, Claus"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Weidinger, Elif"],["dc.contributor.author","Jobst, Andrea"],["dc.contributor.author","Hoell, Imke"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Yeganeh-Doost, Peyman"],["dc.contributor.author","Strube, Wolfgang"],["dc.contributor.author","Quast, Silke"],["dc.contributor.author","Mueller, Norbert"],["dc.contributor.author","Wobrock, Thomas"],["dc.date.accessioned","2018-11-07T09:51:15Z"],["dc.date.available","2018-11-07T09:51:15Z"],["dc.date.issued","2015"],["dc.description.abstract","Despite many pharmacological and psychosocial treatment options, schizophrenia remains a debilitating disorder. Thus, new treatment strategies rooted in the pathophysiology of the disorder are needed. Recently, vagus nerve stimulation (VNS) has been proposed as a potential treatment option for various neuropsychiatric disorders including schizophrenia. The objective of this study was to investigate for the first time the feasibility, safety and efficacy of transcutaneous VNS in stable schizophrenia. A bicentric randomized, sham-controlled, double-blind trial was conducted from 2010 to 2012. Twenty schizophrenia patients were randomly assigned to one of two treatment groups. The first group (active tVNS) received daily active stimulation of the left auricle for 26 weeks. The second group (sham tVNS) received daily sham stimulation for 12 weeks followed by 14 weeks of active stimulation. Primary outcome was defined as change in the Positive and Negative Symptom Scale total score between baseline and week 12. Various other secondary measures were assessed to investigate safety and efficacy. The intervention was well tolerated with no relevant adverse effects. We could not observe a statistically significant difference in the improvement of schizophrenia psychopathology during the observation period. Neither psychopathological and neurocognitive measures nor safety measures showed significant differences between study groups. Application of tVNS was well tolerated, but did not improve schizophrenia symptoms in our 26-week trial. While unsatisfactory compliance questions the feasibility of patient-controlled neurostimulation in schizophrenia, the overall pattern of symptom change might warrant further investigations in this population."],["dc.description.sponsorship","CerboMed GmbH, Erlangen, Germany"],["dc.identifier.doi","10.1007/s00406-015-0618-9"],["dc.identifier.isi","000361397100006"],["dc.identifier.pmid","26210303"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35876"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.title","Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","148"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of the European Academy of Dermatology and Venereology"],["dc.bibliographiccitation.lastpage","155"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Brehmer, Franziska"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.contributor.author","Daeschlein, G."],["dc.contributor.author","Ahmed, R."],["dc.contributor.author","Pfeiffer, S."],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Simon, D."],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Wandke, Dirk"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T10:04:03Z"],["dc.date.available","2018-11-07T10:04:03Z"],["dc.date.issued","2015"],["dc.description.abstract","BackgroundCold atmospheric plasma (CAP, i.e. ionized air) is an innovating promising tool in reducing bacteria. ObjectiveWe conducted the first clinical trial with the novel PlasmaDerm((R)) VU-2010 device to assess safety and, as secondary endpoints, efficacy and applicability of 45s/cm(2) cold atmospheric plasma as add-on therapy against chronic venous leg ulcers. MethodsFrom April 2011 to April 2012, 14 patients were randomized to receive standardized modern wound care (n=7) or plasma in addition to standard care (n=7) 3x per week for 8weeks. The ulcer size was determined weekly (Visitrak((R)), photodocumentation). Bacterial load (bacterial swabs, contact agar plates) and pain during and between treatments (visual analogue scales) were assessed. Patients and doctors rated the applicability of plasma (questionnaires). ResultsThe plasma treatment was safe with 2 SAEs and 77 AEs approximately equally distributed among both groups (P=0.77 and P=1.0, Fisher's exact test). Two AEs probably related to plasma. Plasma treatment resulted in a significant reduction in lesional bacterial load (P=0.04, Wilcoxon signed-rank test). A more than 50% ulcer size reduction was noted in 5/7 and 4/7 patients in the standard and plasma groups, respectively, and a greater size reduction occurred in the plasma group (plasma -5.3cm(2), standard: -3.4cm(2)) (non-significant, P=0.42, log-rank test). The only ulcer that closed after 7weeks received plasma. Patients in the plasma group quoted less pain compared to the control group. The plasma applicability was not rated inferior to standard wound care (P=0.94, Wilcoxon-Mann-Whitney test). Physicians would recommend (P=0.06, Wilcoxon-Mann-Whitney test) or repeat (P=0.08, Wilcoxon-Mann-Whitney test) plasma treatment by trend. ConclusionCold atmospheric plasma displays favourable antibacterial effects. We demonstrated that plasma treatment with the PlasmaDerm((R)) VU-2010 device is safe and effective in patients with chronic venous leg ulcers. Thus, larger controlled trials and the development of devices with larger application surfaces are warranted."],["dc.identifier.doi","10.1111/jdv.12490"],["dc.identifier.isi","000346733800024"],["dc.identifier.pmid","24666170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38612"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1468-3083"],["dc.relation.issn","0926-9959"],["dc.title","Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm (R) VU-2010): results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT01415622)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Ophthalmology Retina"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Klingelhöfer, Anthea"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Striebe, Nina-Antonia"],["dc.contributor.author","Storch, Marcus Werner"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Koscielny, Juergen"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2021-06-01T10:49:52Z"],["dc.date.available","2021-06-01T10:49:52Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1016/j.oret.2021.04.013"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86440"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","2468-6530"],["dc.title","Risk factors for Severe Bleeding Complications in Vitreoretinal Surgery and the Role of Antiplatelet or Anticoagulant Agents"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e11911"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","JMIR Research Protocols"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Nühnen, Viktoria P"],["dc.contributor.author","Pfützner, Wolfgang"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Laubach, Hans-Joachim"],["dc.contributor.author","Boehncke, Wolf-Henning"],["dc.contributor.author","Liebmann, Joerg"],["dc.contributor.author","Born, Matthias"],["dc.contributor.author","Schön, Michael P"],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2020-12-10T18:43:05Z"],["dc.date.available","2020-12-10T18:43:05Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.2196/11911"],["dc.identifier.eissn","1929-0748"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78189"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","aos.14940"],["dc.bibliographiccitation.firstpage","295"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","301"],["dc.bibliographiccitation.volume","100"],["dc.contributor.affiliation","Gebler, Marie; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Pfeiffer, Sebastian; 2\r\nDepartment of Research, Teaching and Clinical Science University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Callizo, Josep; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Hoerauf, Hans; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Feltgen, Nicolas; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.author","Gebler, Marie"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bemme, Sebastian"],["dc.date.accessioned","2021-07-05T14:57:41Z"],["dc.date.available","2021-07-05T14:57:41Z"],["dc.date.issued","2021"],["dc.date.updated","2022-06-14T21:23:28Z"],["dc.description.abstract","Abstract Purpose To assess the incidence of cystoid macular oedema (CME) diagnosed by spectral domain optical coherence tomography (SD‐OCT) after primary rhegmatogenous retinal detachment (RRD) surgery. Methods From April 2016 to October 2017, 150 eyes of 150 patients presenting with primary RRD were included consecutively in this prospective single‐centre study. Patients with the following characteristics were excluded: previous vitreoretinal surgery, combined cataract surgery, preoperatively presentation with any intraocular or systemic inflammatory condition, visible macular oedema or epiretinal membrane (ERM) on funduscopy. SD‐OCT (Spectralis, Heidelberg Engineering) was conducted 3 and 6 weeks after surgery. Results One hundred and twenty‐eight of the 150 patients completed the study, of whom 107 (age: 61.7 ± 11.5 years, mean ± SD) showed successful retinal attachment during follow‐up visits. The most frequent operation method was scleral buckling (54.2%), followed by vitrectomy (25.2%) and the combination of both techniques (20.6%). Postoperative SD‐OCT revealed CME, neurosensory detachment and ERM in 18.7, 31.8 and 32.7% of all cases, respectively. The risk of postoperative CME was significantly elevated in patients with ERM (42.9 versus 6.9%, p < 0.001). In addition, patients with initial detachment of the macula had more postoperative CME (26.5 versus 11.1%, p = 0.044). BCVA improvement was significantly lower in patients with CME compared to patients without 6 weeks after surgery for macula‐on RRD. Conclusions This prospective study confirmed that postoperative CME is a frequent complication after RRD surgery; we identified ERM and macula‐off RRD as potential risk factors. As CME potentially delays visual recovery, postoperative follow‐ups should include SD‐OCT."],["dc.identifier.doi","10.1111/aos.14940"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87706"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-441"],["dc.relation.eissn","1755-3768"],["dc.relation.issn","1755-375X"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Incidence and risk factors for macular oedema after primary rhegmatogenous retinal detachment surgery: a prospective single‐centre study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","370"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Cells"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Barkovits, Katalin"],["dc.contributor.author","Kruse, Niels"],["dc.contributor.author","Linden, Andreas"],["dc.contributor.author","Tönges, Lars"],["dc.contributor.author","Pfeiffer, Kathy"],["dc.contributor.author","Mollenhauer, Brit"],["dc.contributor.author","Marcus, Katrin"],["dc.date.accessioned","2020-12-10T18:47:00Z"],["dc.date.available","2020-12-10T18:47:00Z"],["dc.date.issued","2020"],["dc.description.sponsorship","H2020 Society"],["dc.identifier.doi","10.3390/cells9020370"],["dc.identifier.eissn","2073-4409"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78607"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.publisher","MDPI"],["dc.relation.eissn","2073-4409"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0241005"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Gebest, Julia"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.editor","Grzybowski, Andrzej"],["dc.date.accessioned","2021-04-14T08:31:16Z"],["dc.date.available","2021-04-14T08:31:16Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1371/journal.pone.0241005"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17683"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83535"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1932-6203"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Influence of pars plana vitrectomy for macular surgery on the medium term intraocular pressure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","24096"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Berndzen, Lars"],["dc.contributor.author","Raber, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Paul, Christoph"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bemme, Sebastian"],["dc.date.accessioned","2022-01-11T14:08:03Z"],["dc.date.available","2022-01-11T14:08:03Z"],["dc.date.issued","2021"],["dc.description.abstract","The primary objective was to create and establish a new formula that predicts the individual probability of macular hole closure for eyes with full thickness macular holes (FTMH) accompanied by vitreomacular traction (VMT) which received enzymatic vitreolysis using intravitreally administered ocriplasmin. The secondary objective was to evaluate the forecast reliability of a previously published formula for VMT resolution in VMT-only eyes (Odds IVO-Success  = e Intercept  × OR years  × OR ln(µm) ; Probability IVO-Success  = Odds IVO-Success /(Odds IVO-Success  + 1)) on VMT resolution using the current dataset of eyes with FTMH accompanied by VMT. Retrospective analysis of the OASIS, ORBIT, and INJECT-studies. Patients with FTMH and VMT with complete information (n = 213) were included. The effect of gender, age, FTMH diameter, lens status and the presence of epiretinal membranes (ERM) on FTMH closure was assessed using separate univariate logistic regression analyses. With regard to VMT release separate univariate regression analyses were carried out and results were compared with formerly published data of VMT resolution in eyes with VMT only. Overall, 126 eyes (63%) experienced VMT resolution within 28 days. Younger age (p < 0.0001) and VMT diameter (p = 0.041) had a significant impact on VMT release. Overall, 81 eyes (38%) treated with ocriplasmin showed FTMH closure within 28 days. Univariate analysis of the different predictors analyzed revealed that FTMH diameter < 250 µm had a significant impact on treatment success (p = 0.0495). It was not possible to calculate and establish a new multivariate formula that can predict the individual FTMH closure probability for eyes with FTMHs and VMT. However, the results of VMT release prediction in eyes with FTMHs accompanied by VMT matched the prediction of VMT release in eyes with VMT only when using the previously published formula. All in all, predictors for calculating the individual probability of VMT resolution on the one hand and FTMH closure on the other hand are different suggesting diverse pathophysiological mechanisms."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1038/s41598-021-03509-z"],["dc.identifier.pii","3509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/97924"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-507"],["dc.relation.eissn","2045-2322"],["dc.rights","CC BY 4.0"],["dc.title","Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]